{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:07:59Z","timestamp":1783822079191,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007102","name":"Zagazig University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007102","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To compare the effectiveness of dienogest (DIE) and norethisterone acetate (NETA) regimens in the treatment of endometrial hyperplasia (EH) without atypia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants were premenopausal women with irregular uterine bleeding, and endometrial hyperplasia without atypia on endometrial biopsy. Enrolled patients were randomly allocated into two groups: group I got DIE 2\u00a0mg\/day (orally Visanne) for 14\u00a0days (10th to the 25th day of cycle) while group II received between the 16th and 25th day of the cycle, norethisterone acetate (NETA) 15\u00a0mg\/d (orally Primolut Nor) was administered for 10\u00a0days. Both groups continued the therapy for six months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The DIE group showed a higher resolution (32.7%) and regression (57.7%) than NETA group (31% &amp; 37.9%, respectively) with significant regression (<jats:italic>p<\/jats:italic>\u2009=\u20090.039). No progression in DIE group while four (6.9%) women in NETA group were recorded a progression to complex type without a significance. Also, NETA group showed a significant persistence rate (22.5%) than DIE group (3.8%) (<jats:italic>p<\/jats:italic>\u2009=\u20090.005). Also number in NETA group managed by hysterectomy with significant difference (<jats:italic>p<\/jats:italic>\u2009=\u20090.042).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>If used as first-line treatment, Dienogest produces a better rate of regression and a lower incidence of hysterectomy than Norethisterone Acetate does when used in EH without atypia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-023-07015-7","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:02:30Z","timestamp":1680516150000},"page":"947-952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia"],"prefix":"10.1007","volume":"308","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6637-6719","authenticated-orcid":false,"given":"Ehab F.","family":"Girbash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala E.","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein M.","family":"Abdeldayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"issue":"1","key":"7015_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00404-014-3161-4","volume":"290","author":"Y Tasci","year":"2014","unstructured":"Tasci Y, Polat OG, Ozdogan S, Karcaaltincaba D, Seckin L, Erkaya S (2014) Comparison of the efficacy of micronized progesterone and lynestrenol in treatment of simple endometrial hyperplasia without atypia. Arch Gynecol Obstet 290(1):83\u201386","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"7015_CR2","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jmig.2012.05.009","volume":"19","author":"AJ Armstrong","year":"2012","unstructured":"Armstrong AJ, Hurd WW, Elguero S, Barker NM, Zanotti KM (2012) Diagnosis and management of endometrial hyperplasia. J Minim Invasive Gynecol 19(5):562\u2013571","journal-title":"J Minim Invasive Gynecol"},{"issue":"5","key":"7015_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/00006254-200405000-00025","volume":"59","author":"BE Montgomery","year":"2004","unstructured":"Montgomery BE, Daum GS, Dunton CJ (2004) Endometrial hyperplasia: a review. Obstet Gynecol Surv 59(5):368\u2013378","journal-title":"Obstet Gynecol Surv"},{"issue":"1","key":"7015_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00006254-198601000-00021","volume":"41","author":"RJ Kurman","year":"1986","unstructured":"Kurman RJ, Kaminski PF, Norris HJ (1986) The behavior of endometrial hyperplasia. A long-term study of \u2018\u201cuntreated\u201d\u2019 hyperplasia in 170 patients. Obstet Gynecol Surv 41(1):58\u201361","journal-title":"Obstet Gynecol Surv"},{"issue":"2","key":"7015_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1006\/gyno.2000.5955","volume":"79","author":"CA Amezcua","year":"2000","unstructured":"Amezcua CA, Lu JJ, Felix JC, Stanczyk FZ, Zheng W (2000) Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol 79(2):169\u2013176","journal-title":"Gynecol Oncol"},{"issue":"1","key":"7015_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/0002-9378(89)90103-8","volume":"160","author":"A Ferenczy","year":"1989","unstructured":"Ferenczy A, Gelfand M (1989) The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 160(1):126\u2013131","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"7015_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0029-7844(97)00297-4","volume":"90","author":"TC Randall","year":"1997","unstructured":"Randall TC, Kurman RJ (1997) Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90(3):434\u2013440","journal-title":"Obstet Gynecol"},{"issue":"1","key":"7015_CR8","first-page":"23","volume":"32","author":"M Sanam","year":"2011","unstructured":"Sanam M, Ziba O (2011) Desogestrel + ethinylestradiol versus levonorgestrel + ethinylestradiol. Which one has better affect on acne, hirsutism, and weight change. Saudi Med J 32(1):23\u201326","journal-title":"Saudi Med J"},{"issue":"1","key":"7015_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijgo.2007.06.041","volume":"100","author":"H Li","year":"2008","unstructured":"Li H, Chen X, Qiao J (2008) Letrozole as primary therapy for endometrial hyperplasia in young women. Int J Gynecol Obstet 100(1):10\u201312","journal-title":"Int J Gynecol Obstet"},{"key":"7015_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1447-0756.2009.01076.x","volume":"35","author":"M Momoeda","year":"2009","unstructured":"Momoeda M, Harada T, Terakawa N, Aso T, Fukunaga M, Hagino H et al (2009) Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res 35:1069\u20131076","journal-title":"J Obstet Gynaecol Res"},{"key":"7015_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.steroids.2010.08.010","volume":"76","author":"Y Shimizu","year":"2011","unstructured":"Shimizu Y, Mita S, Takeuchi T, Notsu T, Mizuguchi K, Kyo S (2011) Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids 76:60\u201367","journal-title":"Steroids"},{"key":"7015_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.steroids.2007.10.003","volume":"73","author":"S Sasagawa","year":"2008","unstructured":"Sasagawa S, Shimizu Y, Kami H, Takeuchi T, Mita S, Imada K et al (2008) Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 73:222\u2013231","journal-title":"Steroids"},{"key":"7015_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jmig.2013.04.020","volume":"20","author":"M Kodama","year":"2013","unstructured":"Kodama M, Onoue M, Otsuka H, YadaHashimoto N, Saeki N, Kodama T et al (2013) Efficacy of dienogest in thinning the endometrium before hysteroscopic surgery. J Minim Invasive Gynecol 20:790\u2013795","journal-title":"J Minim Invasive Gynecol"},{"key":"7015_CR14","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds) (2014). WHO Classification of Tumours of Female Reproductive Organs, edition 4. Lyon, IARC. ISBN-13: 978-92-832-2435-8"},{"key":"7015_CR15","first-page":"1755","volume":"40","author":"K Banno","year":"2012","unstructured":"Banno K, Kisu I, Yanokura M, Tsuji K, Masuda K, Ueki A et al (2012) Progestin therapy for endometrial cancer: the potential of fourthgeneration progestin (review). Int J Oncol 40:1755\u20131762","journal-title":"Int J Oncol"},{"key":"7015_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1447-0578.2007.00189.x","volume":"6","author":"M Irahara","year":"2007","unstructured":"Irahara M, Harada T, Momoeda M, Tamaki Y (2007) Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Reprod Med Biol 6:223\u2013228","journal-title":"Reprod Med Biol"},{"key":"7015_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jmig.2011.12.020","volume":"19","author":"E Cicinelli","year":"2012","unstructured":"Cicinelli E, Pinto V, Quattromini P, Fucci MR, Lepera A, Mitola PC et al (2012) Endometrial preparation with estradiol plus dienogest (Qlaira) for office hysteroscopic polypectomy: randomized pilot study. J Minim Invasive Gynecol 19:356\u2013359","journal-title":"J Minim Invasive Gynecol"},{"key":"7015_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000321390","volume":"72","author":"O Ozdegirmenci","year":"2011","unstructured":"Ozdegirmenci O, Kayikcioglu F, Bozkurt U, Akgul MA, Haberal A (2011) Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Gynecol Obstet Invest 72:10\u201314","journal-title":"Gynecol Obstet Invest"},{"issue":"2","key":"7015_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000477618","volume":"83","author":"G Uysal","year":"2018","unstructured":"Uysal G, Acmaz G, Madendag Y, Cagli F, Akkaya H, Madendag I, Karakilic EU (2018) The efficacy of dienogest in the treatment of simple endometrial hyperplasia without atypia. Gynecol Obstet Invest 83(2):151\u2013155","journal-title":"Gynecol Obstet Invest"},{"issue":"1","key":"7015_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1933719112459243","volume":"20","author":"MT Ismail","year":"2013","unstructured":"Ismail MT, Fahmy DM, Elshmaa NS (2013) Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia. Reprod Sci 20(1):45\u201350","journal-title":"Reprod Sci"},{"key":"7015_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00404-013-2983-9","volume":"2","author":"M Ziller","year":"2014","unstructured":"Ziller M, Ziller V, Haas G, Rex J, Kostev K (2014) Risk of venous thrombosis in users of hormonal contraceptives in German gynaecological practices: a patient database analysis. Arch Gynecol Obstet 2:413\u2013419","journal-title":"Arch Gynecol Obstet"},{"key":"7015_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.thromres.2015.11.038","volume":"137","author":"K Sugiura","year":"2016","unstructured":"Sugiura K, Kobayashi T, Ojima T (2016) Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res 137:11\u201316","journal-title":"Thromb Res"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-023-07015-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-023-07015-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-023-07015-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T13:08:45Z","timestamp":1689340125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-023-07015-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["7015"],"URL":"https:\/\/doi.org\/10.1007\/s00404-023-07015-7","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Before enrolling in our trial, we obtained written informed permission from every participant, and they were all free to withdraw at any moment throughout follow-up. The Faculty of Medicine at Zagzig University in Egypt's Institutional Review Board and ethics committee gave their approval to the study's protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}